NCT03933696Completed
Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2
Light, Metabolic Syndrome and Alzheimer's Disease: A Non-Pharmocological Approach
Source: ClinicalTrials.gov · Last updated 13 Jul 2026
Brief summary (registry, in English)
To test the long term effect of a light treatment on cognition, sleep and metabolism in patients with Mild cognitive impairment (MCI) or mild Alzheimer's disease or related dementia (ADRD).
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 25 (actual)
- First submitted
- 25 Apr 2019
- Start date
- 2 Jan 2019
- Primary completion date
- 31 May 2025
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Diseases
- Alzheimer disease
- NCT number
- NCT03933696
What you commit to
- Study type: Interventional
- Participants enrolled: 25
- From 2 Jan 2019 to the primary completion date, 31 May 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- insulin-dependent diabetes patients
Other
- Blindness
- macular degeneration
- severe sleep apnea
Who the study is looking for
- Mild cognitive impairment
- Mild Alzheimer's Disease
- Sleep Disturbance
- Live at home
Age in the registry: 55 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Rutgers University Coordinator of this site? Confirm its status | New Brunswick | United States | Unknown status |
| Icahn School of Medicine at Mount Sinai Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.